A database of FDA approved therapeutic peptides and proteins
ID1837 | ThPPIDTh1226 | NameDinutuximab | Peptide SequenceNA Full view | Length0 | Functional ClassificationIIIc | DiseaseCancer | Brandunituxin | CompanyNA | Physical Appearancesterile, preservative-free, clear/colorless to slightly opalescent solution | Route of AdministartionIntravenous | CategoryAntibody, Immunosuppresive agent, Antineoplastic agent | TargetGanglioside GD2 (small molecule) |
ID1838 | ThPPIDTh1227 | NameEfmoroctocog alfa | Peptide SequenceNA Full view | Length0 | Functional ClassificationIb | DiseaseHematological Disorders | BrandELOCTA | CompanyNA | Physical AppearancePowder and solvent for solution for injection | Route of AdministartionIntravenous | CategoryAntihemophilic Factor | TargetNA |
ID1839 | ThPPIDTh1228 | NameFactor IX Complex (Human) | Peptide SequenceNA Full view | Length0 | Functional ClassificationIb | DiseaseHematological Disorders | BrandAlphaNine SD or Mononine | Company | Physical AppearancePowder and solvent for solution for injection | Route of AdministartionIntravenous | CategoryAntihemophilic agent | TargetNA |
ID1842 | ThPPIDTh1230 | NameHuman Varicella-Zoster Immune Globulin | Peptide SequenceNA Full view | Length0 | Functional ClassificationIIIa | DiseaseInfectious Disease | BrandVARIZIG | CompanyNA | Physical Appearancelyophilized powder for solution | Route of AdministartionIntramuscular | CategoryAntibody | Targetvaricella zoster virus |
ID1843 | ThPPIDTh1231 | NameIbritumomab tiuxetan | Peptide SequenceHeavy chain: QAYLQQS Full view | Length652 | Functional ClassificationIIIc | DiseaseCancer | BrandZevalin | CompanySpectrum Pharmaceuticals B.V. | Physical AppearanceColourless Solution | Route of AdministartionIntravenous | CategoryAntibody, Immunosuppressive Agents | TargetB-lymphocyte antigen CD20, Low affinity immunoglobulin gamma Fc region receptor III-B, Complement C1r subcomponent, Complement C1q subcomponent subunit A, Complement C1q subcomponent subunit B, Complement C1q subcomponent subunit C, Low affinity immunoglobulin gamma Fc region receptor III-A, Complement C1s subcomponent, High affinity immunoglobulin gamma Fc receptor I, Low affinity immunoglobulin gamma Fc region receptor II-a,Low affinity immunoglobulin gamma Fc region receptor II-b, Low affinity immunoglobulin gamma Fc region receptor II-c |
ID1848 | ThPPIDTh1236 | NameSipuleucel-T | Peptide SequenceNA Full view | Length0 | Functional ClassificationIIIc | DiseaseCancer | BrandProvenge | CompanyNA | Physical AppearanceSolution | Route of AdministartionIntravenous | CategoryAntineoplastic and Immunomodulating Agents | TargetProstatic acid phosphatase |
ID1849 | ThPPIDTh1237 | NameSomatropin recombinant | Peptide SequenceFPTIPLSRLFDNAMLRAHRL Full view | Length191 | Functional ClassificationIb | DiseaseHormonal Disorders | BrandBioTropin | CompanyBiotech General | Physical AppearancePowder and Solvent for Solution | Route of AdministartionSubcutaneous | CategoryHormones, Hormone Substitutes, and Hormone Antagonists | TargetGrowth hormone receptor, Prolactin receptor |
ID1851 | ThPPIDTh1238 | NameSusoctocog alfa | Peptide SequenceAIRRYYLGAVELSWDYRQSE Full view | Length1448 | Functional ClassificationIb | DiseaseHematological Disorders | BrandObizur | CompanyNA | Physical AppearancePowder and solvent for solution for injection. | Route of AdministartionIntravenous | CategoryBlood coagulation factors, Antihaemorrhagics | Targetvon Willebrand factor |
ID1852 | ThPPIDTh1239 | NameThrombomodulin Alfa | Peptide SequenceNA Full view | Length0 | Functional ClassificationIb | DiseaseHematological Disorders | BrandRecomodulin (in Japan only) | CompanyAsahi Kasei Pharma Corp | Physical Appearancelyophilized powder for solution | Route of AdministartionIntravenous | CategoryAnticoagulant agent, Antiplatelet agent | TargetProthrombin, Coagulation factor V |